SeekingAlpha · Oct 14, 2026
Aktis Oncology: Padcev Is Building The Market It Wants
Aktis Oncology is undervalued, trading below IPO price despite robust cash reserves and two independent clinical programs. Read more on AKTS stock here.
AK
NASDAQ · AKTS
Aktis Oncology, Inc.
Healthcare · Biotechnology
$15.73
Up+$0.72 (+4.58%)
Updated Oct 28, 2026, 1:26 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.06B
- P/E ratio
- 0
- Dividend yield
- 0.00%
- 52-week range
- $0.03 – $34.19
- Volume
- 150K
- Avg. volume
- 374.39K
Price performance · AKTS
AKTS price history
1M range · 0 trading sessions · Daily adjusted prices
AKTS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest AKTS news
The latest Smart Investors Daily articles mentioning AKTS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AKTS research
Overview
Company profile and research snapshot.
Company profile
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.92
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 2, 2026 | Wedbush | Outperform | — |
| Sep 9, 2026 | Oppenheimer | Outperform | — |
| Aug 19, 2026 | Wedbush | Outperform | — |
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Jul 14, 2026 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 2, 2026
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target
Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.
Yahoo · Oct 1, 2026
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumorsEnrollment is ongoing in the Phase 1b BActinium-1 clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); preliminary data expected in 2027 BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potentia
Benzinga · Oct 1, 2026
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519
Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumorsEnrollment is ongoing in the Phase 1b BActinium-1 clinical trial of
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
